Dantong Sun - Publications, H-index & Citations

Dantong Sun

Anhui Medical University

19H指数

64论文数

1.6K被引数

收录论文 24

发表时间

SMARCA4 deficiency contributes to platinum resistance in non-small cell lung cancer by activating the NF-κB-BIRC2/BIRC3 signaling axis SMARCA4 缺失通过激活 NF-κB-BIRC2/BIRC3 信号轴促进非小细胞肺癌对铂类药物的耐药性

Journal of Thoracic Disease

IF1.9

2026-06-30

PREAI

Li, Yufeng; Zhou, Na; Zhang, Lin; Huo, Xingfa; Zhang, Yuming; Yang, Fangfang; Zhang, Xuchen; Zhang, Chuantao; Sun, Dantong; Hou, Helei

CUL4A promotes glycolytic metabolism of fibroblast-like synoviocytes by targeting FGF2 in rheumatoid arthritis CUL4A通过靶向FGF2促进类风湿关节炎中成纤维样滑膜细胞的糖酵解代谢

Biochemical Pharmacology

IF5.6

2026-02-10

PREAI

Dantong Sun; Jun Wang; Xue Yang; Han Shu; Yongfeng Cheng; Ying Chen; Qingqing Xia; Facai Wang; Siwei Deng; Jun Li; Xiao-Feng Li; Biao Song

Lactylation: the metabolic–immune hub in autoimmune diseases 乳酰化：自身免疫性疾病中的代谢-免疫枢纽

Frontiers in Immunology

IF5.9

2025-12-18

OAAI

Qingqing Xia†; Dantong Sun†; Ke Wan†; Chengcheng Liu; Han Shu; Miao Wang; Tongsheng Zhou; Ying Chen; Xue Yang; Xiao-Feng Li‡; Biao Song‡; Facai Wang‡

A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma 基于队列的多组学分析鉴定出eIF5B/PD-L1/CD44复合物的核转位是克服ARID1A缺失型肺腺癌奥希替尼耐药的靶点

hematology oncology

IF13.5

2025-01-07

OAAI

Sun, Dantong; Hou, Helei; Feng, Feiyue; Wu, Weizheng; Tan, Jingyu; Xie, Tongji; Liu, Jiayu; Wang, Jinsong; Qian, Haili; Li, Junling; Xing, Puyuan

Impact of PIK3CA and cell cycle pathway alterations on durvalumab efficacy in head and neck squamous cell carcinoma

ANNALS OF ONCOLOGY

IF65.4

2024-10-01

PREAI

Kim, D.; Lim, S.; Kim, H.; Kang, E.; Ahn, H.; Lee, Y.; Sun, D.; Kwon, J.; Lee, S.; Lee, H.; Kim, M.; Keam, B.; Park, K.; Shin, S.; Yun, H.

CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN/AKT signaling phosphorylation and neutrophil chemotaxis CXCL5通过PXN/AKT信号磷酸化和中性粒细胞趋化作用上调肺癌PD-L1表达，从而阻碍CD8 T细胞免疫

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

IF12.8

2024-07-22

OAAI

Sun, Dantong; Tan, Lipin; Chen, Yongbing; Yuan, Qiang; Jiang, Kanqiu; Liu, Yangyang; Xue, Yuhang; Zhang, Jinzhi; Cao, Xianbao; Xu, Minzhao; Luo, Yang; Xu, Zhonghua; Xu, Zhonghen; Xu, Weihua; Shen, Mingjing

Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy

JOURNAL OF BIOMEDICAL SCIENCE

IF12.1

2024-01-29

OAAI

Sun, Dantong; Qian, Haili; Li, Junling; Xing, Puyuan

MET fusions are targetable genomic variants in the treatment of advanced malignancies

CELL COMMUNICATION AND SIGNALING

IF8.9

2024-01-09

OAAI

Sun, Dantong; Xing, Xiaoming; Wang, Yongjie; Hou, Helei

Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency

CELL COMMUNICATION AND SIGNALING

IF8.9

2023-03-03

OAAI

Sun, Dantong; Feng, Feiyue; Teng, Fei; Xie, Tongji; Wang, Jinsong; Xing, Puyuan; Qian, Haili; Li, Junling

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer

JOURNAL OF TRANSLATIONAL MEDICINE

IF7.5

2023-02-25

OAAI

Sun, Dantong; Wu, Weizheng; Wang, Li; Qu, Jialin; Han, Qiman; Wang, Huiyun; Song, Shanai; Liu, Ning; Wang, Yongjie; Hou, Helei

Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China toripalimab联合铂类紫杉醇新辅助化疗治疗 ⅱ-ⅲ 期非小细胞肺癌: 一项单中心、单臂、I期中国研究

INVESTIGATIONAL NEW DRUGS

IF2.7

2022-12-12

PREAI

Hou, Helei; Wang, Yongjie; Sun, Dantong; Zhu, Jingjuan; Jiang, Man; Zhang, Xuchen; Zhou, Na; Zhang, Chuantao; Li, Tianjun; Zhang, Xiaochun

ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production

CELL COMMUNICATION AND SIGNALING

IF8.9

2022-10-13

OAAI

Sun, Dantong; Qian, Haili; Wang, Jinsong; Xie, Tongji; Teng, Fei; Li, Junling; Xing, Puyuan

ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer

MOLECULAR MEDICINE

IF6.4

2021-10-29

OAAI

Sun, Dantong; Teng, Fei; Xing, Puyuan; Li, Junling

Loss of ARID1A expression promotes lung adenocarcinoma metastasis and predicts a poor prognosis ARID1A表达缺失促进肺腺癌转移并预测不良预后

CELLULAR ONCOLOGY

IF4.8

2021-06-09

PREAI

Sun, Dantong; Zhu, Yan; Zhao, Han; Bian, Tiantian; Li, Tianjun; Liu, Kewei; Feng, Lizong; Li, Hong; Hou, Helei

Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma

CANCER BIOLOGY & THERAPY

IF4.6

2020-11-05

OAAI

Sun, Dantong; Liu, Dong; Liu, Qiaoling; Hou, Helei

Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing

FRONTIERS IN ONCOLOGY

IF3.3

2020-10-29

OAAI

Sun, Dantong; Yan, Weihua; Zhu, Hua; Liu, Qiaoling; Hou, Helei

Advancement in research and therapy ofNF1mutant malignant tumors

CANCER CELL INTERNATIONAL

IF6

2020-10-09

OAAI

Tao, Junyan; Sun, Dantong; Dong, Lina; Zhu, Hua; Hou, Helei

The role of CD28 in the prognosis of young lung adenocarcinoma patients

BMC CANCER

IF3.4

2020-09-23

OAAI

Sun, Dantong; Tian, Lu; Bian, Tiantian; Zhao, Han; Tao, Junyan; Feng, Lizong; Liu, Qiaoling; Hou, Helei

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer

MOLECULAR MEDICINE

IF6.4

2020-08-13

OAAI

Sun, Dantong; Tian, Lu; Zhu, Yan; Wo, Yang; Liu, Qiaoling; Liu, Shihai; Li, Hong; Hou, Helei

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC NSCLC中MDM2扩增诱导的第一代egfr-tkis原发性耐药

MOLECULAR MEDICINE

IF6.4

2020-07-01

OAAI

Sun, Dantong; Zhu, Yan; Zhu, Jingjuan; Tao, Junyan; Wei, Xiaojuan; Wo, Yang; Hou, Helei

研究方向